Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Thyroid gland

Genetic insight into antithyroid drug-induced agranulocytosis in a European population

The HLA allele HLA-B*27:05 on chromosome 6 is associated with antithyroid drug-induced agranulocytosis in white European individuals, according to a new genome-wide association study (GWAS). Three single nucleotide polymorphisms (SNPs; rs652888, rs199564443 and rs1071816) associated with this potentially life-threatening adverse effect of treating hyperthyroidism were also identified, one of which (rs1071816) was in moderate linkage disequilibrium with HLA-B*27:05. The findings, which complement two earlier GWAS in Asian populations, are a step towards precision medicine for antithyroid drug-induced agranulocytosis, which could see carriers of HLA-B*27:05 or the three SNPs being offered alternative treatments for hyperthyroidism.


  1. 1

    Hallberg, P et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol. (2016)

Download references


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Holmes, D. Genetic insight into antithyroid drug-induced agranulocytosis in a European population. Nat Rev Endocrinol 12, 374 (2016).

Download citation


Quick links